CA2096159C - Peptides that induce antibodies which neutralize genetically divergent hiv-1 isolates - Google Patents

Peptides that induce antibodies which neutralize genetically divergent hiv-1 isolates Download PDF

Info

Publication number
CA2096159C
CA2096159C CA002096159A CA2096159A CA2096159C CA 2096159 C CA2096159 C CA 2096159C CA 002096159 A CA002096159 A CA 002096159A CA 2096159 A CA2096159 A CA 2096159A CA 2096159 C CA2096159 C CA 2096159C
Authority
CA
Canada
Prior art keywords
seq
peptide
hiv
type
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002096159A
Other languages
English (en)
French (fr)
Other versions
CA2096159A1 (en
Inventor
Hermann Katinger
Florian Ruker
Gottfried Himmler
Thomas Muster
Alexandra Trkola
Martin Purtscher
Georg Maiwald
Franz Steindl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AT98792A external-priority patent/AT403050B/de
Application filed by Individual filed Critical Individual
Publication of CA2096159A1 publication Critical patent/CA2096159A1/en
Application granted granted Critical
Publication of CA2096159C publication Critical patent/CA2096159C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4216—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig
    • C07K16/4225—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig against anti-HIV Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002096159A 1992-05-14 1993-05-13 Peptides that induce antibodies which neutralize genetically divergent hiv-1 isolates Expired - Lifetime CA2096159C (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AT98792A AT403050B (de) 1992-05-14 1992-05-14 Peptide, die antikörper binden
ATA987/92 1992-05-14
US93278792A 1992-08-29 1992-08-29
US932,787 1992-08-29

Publications (2)

Publication Number Publication Date
CA2096159A1 CA2096159A1 (en) 1993-11-15
CA2096159C true CA2096159C (en) 2004-07-20

Family

ID=25594514

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002096159A Expired - Lifetime CA2096159C (en) 1992-05-14 1993-05-13 Peptides that induce antibodies which neutralize genetically divergent hiv-1 isolates

Country Status (6)

Country Link
US (3) US5693752A (online.php)
EP (1) EP0570357B1 (online.php)
JP (1) JP3369246B2 (online.php)
CA (1) CA2096159C (online.php)
DE (2) DE69311764T2 (online.php)
ES (1) ES2053413T3 (online.php)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0580758A4 (en) * 1991-04-18 1995-04-05 Sinai School Medicine RECOMBINANT ANTIBODIES AGAINST HUMAN IMMUNE WEAKNESS VIRUS.
EP0570357B1 (en) * 1992-05-14 1997-06-25 Polymun Scientific Immunbiologische Forschung GmbH Peptides that induce antibodies which neutralize genetically divergent HIV-1 isolates
DE69426725T2 (de) * 1993-09-11 2001-09-06 Polimun Scientific Immunbiologische Forschungsgesellschaft Mbh, Wien Peptide, die neutralisierende antikörper gegen genetisch divergierende hiv-1 stämme, induzieren
ES2293643T5 (es) 1994-10-20 2012-02-02 Institut Pasteur Secuencias nucleotídicas de antígenos retrovíricos vih-1 del grupo (o subgrupo) o.
FR2731225B1 (fr) * 1995-03-03 2003-10-31 Pasteur Institut Peptides de glycoproteine transmembranaire d'enveloppe et de proteine de capside du retrovirus humain du type hiv-1 et peptides presentant avec eux une parente immunologique
GB9424631D0 (en) * 1994-12-06 1995-01-25 Lynxvale Ltd Modulating the immune response
ATE219105T1 (de) * 1995-04-19 2002-06-15 Polymun Scient Immunbio Forsch Monoklonale antikörper gegen hiv-1 und davon hergestellte impfstoffe
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
US6228128B1 (en) 1997-11-10 2001-05-08 Charlotte Johansen Antimicrobial activity of laccases
ES2301241T3 (es) * 1998-06-12 2008-06-16 Mount Sinai School Of Medicine Of The City University Of New York Virus de influenza a atenuados, y composiciones inmunogenicas y formulaciones de vacunas que los contienen.
JP4837827B2 (ja) 1998-06-12 2011-12-14 マウント シナイ スクール オブ メディシン 新規なウイルス増殖方法およびそのためのインターフェロン欠損培養基
US7090848B1 (en) * 1998-08-04 2006-08-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine HIV-1 envelope protein associated with a broadly reactive neutralizing antibody response
DE69941051D1 (de) * 1998-08-04 2009-08-13 Jackson H M Found Military Med Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisier
US7115262B1 (en) 1999-03-16 2006-10-03 The United States Of America As Represented By The Department Of Health And Human Services Chimeric protein for prevention and treatment of HIV infection
WO2001077394A1 (en) * 2000-04-10 2001-10-18 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
US6399067B1 (en) * 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
JP4495969B2 (ja) * 2002-01-17 2010-07-07 ポリマン サイエンティフィック イミューンバイオロジッシュ フォーシュング ゲゼルシャフト ミット ベシュレンクテル ファフツング Ｈｉｖ−１中和抗体を誘導する抗イディオタイプ抗体
CA2525370A1 (en) * 2003-05-06 2004-11-25 The Scripps Research Institute Domain-exchanged binding molecules, methods of use and methods of production
BR122015032743B1 (pt) 2004-06-01 2018-04-03 Mount Sinai School Of Medicine Of New York University Vírus atenuado de influenza de suínos geneticamente engenheirado, formulação imunogênica, formulação farmacêutica, seus usos e métodos para produzir uma vacina
AU2006214563B2 (en) 2005-02-15 2011-08-18 Thymon, L.L.C. Methods and compositions for impairing multiplication of HIV-1
EP1855713B1 (en) * 2005-02-15 2016-04-27 Mount Sinai School of Medicine Genetically engineered equine influenza virus and uses thereof
AU2006235507B2 (en) 2005-04-12 2012-08-30 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
EP2025762A3 (en) 2006-01-17 2009-09-30 Health Research Inc. Heteroduplex tracking assay
US8956627B2 (en) * 2007-04-13 2015-02-17 Duke University Method of inducing antibodies to human immunodeficiency virus involving the administration of MPER peptide-liposome conjugates
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
SMT201800284T1 (it) 2011-06-10 2018-07-17 Univ Oregon Health & Science Glicoproteine cmv e vettori ricombinanti
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
WO2015048635A1 (en) 2013-09-27 2015-04-02 Duke University Mper-liposome conjugates and uses thereof
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3261664A1 (en) 2015-02-26 2018-01-03 Boehringer Ingelheim Vetmedica GmbH Bivalent swine influenza virus vaccine
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
CN108779168A (zh) 2015-12-05 2018-11-09 沃迪奥斯大学医院中心 Hiv结合剂
WO2020012435A1 (en) 2018-07-13 2020-01-16 Lausanne University Hospital Hiv binding agents
EP3996815A2 (en) 2019-07-15 2022-05-18 Lausanne University Hospital Hiv binding agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01501547A (ja) * 1986-06-12 1989-06-01 バイオジェン　ナームローズ　ベンノットシャップ Ｈｉｖ感染の病因に関するペプチド
EP0330359A3 (en) * 1988-02-25 1991-06-05 Bio-Rad Laboratories, Inc. Composition useful in the diagnosis and treating of hiv-1 infection
EP0362910A3 (en) * 1988-08-27 1991-01-09 Akzo N.V. Synthetic peptides immunochemically reactive with hiv-antibodies
EP0570357B1 (en) * 1992-05-14 1997-06-25 Polymun Scientific Immunbiologische Forschung GmbH Peptides that induce antibodies which neutralize genetically divergent HIV-1 isolates

Also Published As

Publication number Publication date
EP0570357A3 (online.php) 1994-04-20
US5866694A (en) 1999-02-02
EP0570357B1 (en) 1997-06-25
US5693752A (en) 1997-12-02
DE69311764T2 (de) 1998-02-05
JPH06293797A (ja) 1994-10-21
US5756674A (en) 1998-05-26
DE570357T1 (de) 1994-07-28
CA2096159A1 (en) 1993-11-15
DE69311764D1 (de) 1997-07-31
EP0570357A2 (en) 1993-11-18
ES2053413T3 (es) 1997-11-16
JP3369246B2 (ja) 2003-01-20
ES2053413T1 (es) 1994-08-01

Similar Documents

Publication Publication Date Title
EP0570357B1 (en) Peptides that induce antibodies which neutralize genetically divergent HIV-1 isolates
McLain et al. Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunized with a 22 amino acid peptide of gp41 expressed on the surface of a plant virus
US6335017B1 (en) Compositions and methods for treating viral infections
Nardelli et al. A chemically defined synthetic vaccine model for HIV-1
HUT51296A (en) Process for producing hn env-coded peptide for producing antibodies for inhibiting human hiv virus in mammalian
EP0492560B1 (en) Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of HIV-1, and related peptides
US6171596B1 (en) Oligomeric HIV-1 envelope glycoproteins
CS68091A2 (en) Synthetic polypeptides
HU219507B (hu) Genetikailag divergens HIV-1-törzsekkel szemben neutralizáló ellenanyagok termelődését kiváltó peptidek
WO1992008491A1 (en) Conjugates of anti-idiotype antibodies and carriers and their use in epitope-directed immunization
Kalyan et al. Immunogenicity of recombinant influenza virus haemagglutinin carrying peptides from the envelope protein of human immunodeficiency virus type 1
US5003043A (en) Peptides representing epitopic sites for the major HTLV-I envelope protein, antibodies thereto, and uses thereof
WO1989005821A1 (en) Hiv-related antigens and antibodies
AU2017251715A1 (en) Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof
Boudet et al. Anti-idiotypic antibodies to the third variable domain of gp120 induce an anti-HIV-1 antibody response in mice
WO1989005820A1 (en) Hiv-related antigens and antibodies
Boudet et al. Single peptide and anti-idiotype based immunizations can broaden the antibody response against the variable V3 domain of HIV-1 in mice
WO1994023746A1 (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
US10660951B2 (en) Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof
Boudet et al. Fine analysis of immunoreactivity of V3 peptides: antibodies specific for V3 domain of laboratory HIV type 1 strains recognize multiple V3 sequences synthesized from field HIV type 1 isolates
AU2006200454A1 (en) Compositions and methods for treating viral infections
McLain et al. Claudine Portal, George P. LomonossoffS and Nigel J. Dimmock* zyxwvutsrqponmlkjihgfedcbaZYXWVUTSRQPONMLKJIHG
AU2006200455A1 (en) Compositions and methods for treating viral infections
AU6655300A (en) Compositions and methods for treating infections

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130513

MKEC Expiry (correction)

Effective date: 20131009